Allergan Inc (AGN)

AGN (NYSE:Drugs)
$170.06
neg -0.51
-0.30%
Today's Range: 169.74 - 170.91 | AGN Avg Daily Volume: 3,186,800
Last Update: 07/25/14 - 4:00 PM EDT
Volume: 1,334,653
YTD Performance: 53.56%
Open: $169.74
Previous Close: $170.57
52 Week Range: $86.95 - $174.49
Oustanding Shares: 297,556,619
Market Cap: 51,181,462,674
6-Month Chart
TheStreet Ratings Grade for AGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 6 6 9
Moderate Buy 0 0 0 0
Hold 6 7 7 4
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 2.23 2.29 2.29 1.86
Latest Dividend: 0.05
Latest Dividend Yield: 0.12%
Dividend Ex-Date: 08/13/14
Price Earnings Ratio: 36.61
Price Earnings Comparisons:
AGN Sector Avg. S&P 500
36.61 40.90 28.96
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
2.38% 88.64% 102.19%
GROWTH 12 Mo 3 Yr CAGR
Revenue 8.50 0.28 0.09
Net Income -10.30 258.69 5.26
EPS -9.80 0.00 0.00
Earnings for AGN:
EBITDA 2.07B
Revenue 6.30B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $1.47 $1.64 $5.79 $8.25
Number of Analysts 10 10 13 11
High Estimate $1.55 $1.70 $5.82 $8.37
Low Estimate $1.44 $1.53 $5.75 $7.74
Prior Year $1.23 $1.35 $4.77 $5.79
Growth Rate (Year over Year) 19.19% 21.70% 21.38% 42.57%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Bullish
Jul 22, 2014 | 8:21 AM EDT
AGN was upgraded from Neutral to Buy, UBS said. $200 price target. The company plans to see more sales growth, while they consider a de...
Bullish
Jul 22, 2014 | 7:21 AM EDT
Shares of AGN now seen reaching $184, according to Leerink Swann. Estimates also increased, as the company is aggressively cutting cost...
The consensus of positives is just too cute.
There are amazing cross currents that make fundamental security analysis hard.
Cheap money and greed from the Allergan bidder's side are strong incentives.
Here are several themes that are still working -- and now you can get in at a bargain.

Allergan Rejects Offer Real Money Pro($)

No thanks!
Bearish
Jun 03, 2014 | 8:02 AM EDT
AGN was downgraded from Outperform to Neutral, Credit Suisse said. $190 price target. Risk/reward is balanced, following the latest bid...
Let's look at how wrong this whole concept is.
You should be watching how DexCom is trading.

Columnist Conversations

Index Chart of the Day: SPX and RUT Divergence SPX vs. RUT (YTD) View Chart »&nbs...
Is this the biotech revolution or the biotech bust? View Small Cap Biotechs Like Never Before: Transparency is...
The S&P 500 index finished the week unchanged, but the VIX was up 5%, the divergence sending a bit of a mi...
Weyerhaeuser has been struggling since testing the 2013 highs last month. The stock extended a powerful...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.